However, inhibiting two immunological checkpoints with anti-PD-1 and anti-CTLA-4 improved PKD outcomes in adult-onset ADPKD mice, while neither monotherapy reduced PKD severity.55 The gene discussed is PDCD1; the disease is autosomal dominant polycystic kidney disease.